BRPI0922475A2 - composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. - Google Patents
composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.Info
- Publication number
- BRPI0922475A2 BRPI0922475A2 BRPI0922475A BRPI0922475A BRPI0922475A2 BR PI0922475 A2 BRPI0922475 A2 BR PI0922475A2 BR PI0922475 A BRPI0922475 A BR PI0922475A BR PI0922475 A BRPI0922475 A BR PI0922475A BR PI0922475 A2 BRPI0922475 A2 BR PI0922475A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13968108P | 2008-12-22 | 2008-12-22 | |
| PCT/GB2009/051755 WO2010073034A1 (en) | 2008-12-22 | 2009-12-22 | Pyrimidine indole derivatives for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0922475A2 true BRPI0922475A2 (pt) | 2017-06-06 |
Family
ID=41682867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922475A BRPI0922475A2 (pt) | 2008-12-22 | 2009-12-22 | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20110053923A1 (pt) |
| EP (1) | EP2379530A1 (pt) |
| JP (1) | JP2012513388A (pt) |
| KR (1) | KR20110094342A (pt) |
| CN (1) | CN102325764A (pt) |
| AR (1) | AR074876A1 (pt) |
| AU (1) | AU2009332745A1 (pt) |
| BR (1) | BRPI0922475A2 (pt) |
| CA (1) | CA2750841A1 (pt) |
| CL (1) | CL2011001536A1 (pt) |
| CO (1) | CO6390107A2 (pt) |
| CR (1) | CR20110349A (pt) |
| CU (1) | CU20110137A7 (pt) |
| DO (1) | DOP2011000203A (pt) |
| EA (1) | EA201100971A1 (pt) |
| EC (1) | ECSP11011156A (pt) |
| IL (1) | IL213470A0 (pt) |
| MX (1) | MX2011006754A (pt) |
| NI (1) | NI201100130A (pt) |
| PE (1) | PE20110894A1 (pt) |
| SG (1) | SG171975A1 (pt) |
| TW (1) | TW201028410A (pt) |
| UY (1) | UY32351A (pt) |
| WO (1) | WO2010073034A1 (pt) |
| ZA (1) | ZA201105395B (pt) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2921576T3 (es) | 2008-12-19 | 2022-08-29 | Vertex Pharma | Compuestos útiles como inhibidores de la quinasa ATR |
| NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| CN106496173A (zh) | 2011-09-30 | 2017-03-15 | 沃泰克斯药物股份有限公司 | 用于制备可用作atr激酶抑制剂的化合物的方法 |
| CN108478577A (zh) | 2012-04-05 | 2018-09-04 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物及其组合疗法 |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| EP3261637B1 (en) * | 2015-02-27 | 2021-05-26 | NantBioScience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| MX2018008507A (es) | 2016-01-11 | 2019-07-04 | Merrimack Pharmaceuticals Inc | Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr). |
| TW201840319A (zh) | 2017-02-24 | 2018-11-16 | 德商拜耳廠股份有限公司 | Atr激酶抑制劑與鐳-223鹽之組合 |
| WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
| JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
| US11660301B2 (en) | 2017-02-24 | 2023-05-30 | Bayer Pharma Aktiengesellschaft | Combination of ATR kinase inhibitors with PARP inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| WO2019014618A1 (en) | 2017-07-13 | 2019-01-17 | Board Of Regents, University Of Texas System | HETEROCYCLIC INHIBITORS OF KINASE ATR |
| US11690911B2 (en) | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
| JP7290627B2 (ja) * | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| EP3720973A1 (en) | 2017-12-08 | 2020-10-14 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
| DK3753937T3 (da) | 2018-02-07 | 2024-02-12 | Wuxi Biocity Biopharmaceutics Co Ltd | Atr-hæmmer og anvendelse deraf |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN112654396B (zh) * | 2018-09-07 | 2025-07-01 | 默克专利股份公司 | 5-吗啉-4-基-吡唑并[4,3-b]吡啶衍生物 |
| WO2020078788A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| TW202128690A (zh) * | 2019-11-21 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡唑并雜芳基類衍生物、其製備方法及其在醫藥上的應用 |
| US20240150333A1 (en) * | 2020-03-20 | 2024-05-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Taf1 inhibitors |
| WO2022094218A1 (en) * | 2020-10-29 | 2022-05-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2280930C (en) | 1997-02-12 | 2010-04-06 | The Regents Of The University Of Michigan | Protein markers for lung cancer and use thereof |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| JP3663382B2 (ja) | 2000-02-15 | 2005-06-22 | スージェン・インコーポレーテッド | ピロール置換２−インドリノン蛋白質キナーゼ阻害剤 |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| CN1473156A (zh) * | 2000-11-10 | 2004-02-04 | - | 嘧啶衍生物及其作为神经肽y受体配体的用途 |
| DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
| US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| BRPI0814503A2 (pt) * | 2007-07-09 | 2017-05-16 | Astrazeneca Ab | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
-
2009
- 2009-12-21 US US12/642,952 patent/US20110053923A1/en not_active Abandoned
- 2009-12-21 TW TW098143945A patent/TW201028410A/zh unknown
- 2009-12-21 UY UY0001032351A patent/UY32351A/es not_active Application Discontinuation
- 2009-12-22 WO PCT/GB2009/051755 patent/WO2010073034A1/en not_active Ceased
- 2009-12-22 AU AU2009332745A patent/AU2009332745A1/en not_active Abandoned
- 2009-12-22 AR ARP090105074A patent/AR074876A1/es unknown
- 2009-12-22 BR BRPI0922475A patent/BRPI0922475A2/pt not_active IP Right Cessation
- 2009-12-22 CA CA2750841A patent/CA2750841A1/en not_active Abandoned
- 2009-12-22 SG SG2011041027A patent/SG171975A1/en unknown
- 2009-12-22 PE PE2011001259A patent/PE20110894A1/es not_active Application Discontinuation
- 2009-12-22 KR KR1020117016261A patent/KR20110094342A/ko not_active Withdrawn
- 2009-12-22 JP JP2011541606A patent/JP2012513388A/ja active Pending
- 2009-12-22 MX MX2011006754A patent/MX2011006754A/es not_active Application Discontinuation
- 2009-12-22 EP EP09795534A patent/EP2379530A1/en not_active Withdrawn
- 2009-12-22 CN CN200980157610XA patent/CN102325764A/zh active Pending
- 2009-12-22 EA EA201100971A patent/EA201100971A1/ru unknown
-
2011
- 2011-06-09 IL IL213470A patent/IL213470A0/en unknown
- 2011-06-21 CL CL2011001536A patent/CL2011001536A1/es unknown
- 2011-06-22 CR CR20110349A patent/CR20110349A/es unknown
- 2011-06-22 NI NI201100130A patent/NI201100130A/es unknown
- 2011-06-22 EC EC2011011156A patent/ECSP11011156A/es unknown
- 2011-06-22 CU CU20110137A patent/CU20110137A7/es unknown
- 2011-06-22 DO DO2011000203A patent/DOP2011000203A/es unknown
- 2011-06-29 CO CO11081450A patent/CO6390107A2/es not_active Application Discontinuation
- 2011-07-21 ZA ZA2011/05395A patent/ZA201105395B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201028410A (en) | 2010-08-01 |
| PE20110894A1 (es) | 2012-01-18 |
| ECSP11011156A (es) | 2011-07-29 |
| DOP2011000203A (es) | 2011-07-15 |
| JP2012513388A (ja) | 2012-06-14 |
| EP2379530A1 (en) | 2011-10-26 |
| SG171975A1 (en) | 2011-07-28 |
| EA201100971A1 (ru) | 2012-01-30 |
| MX2011006754A (es) | 2011-07-20 |
| CL2011001536A1 (es) | 2011-10-14 |
| CR20110349A (es) | 2011-08-05 |
| KR20110094342A (ko) | 2011-08-23 |
| CA2750841A1 (en) | 2010-07-01 |
| NI201100130A (es) | 2012-03-19 |
| CN102325764A (zh) | 2012-01-18 |
| CU20110137A7 (es) | 2012-01-31 |
| ZA201105395B (en) | 2012-03-28 |
| IL213470A0 (en) | 2011-07-31 |
| WO2010073034A1 (en) | 2010-07-01 |
| UY32351A (es) | 2010-07-30 |
| CO6390107A2 (es) | 2012-02-29 |
| AR074876A1 (es) | 2011-02-16 |
| AU2009332745A1 (en) | 2011-06-30 |
| US20110053923A1 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
| BRPI1010937A2 (pt) | composto, uso de um composto, e, método para tratar câncer | |
| BRPI0818426A2 (pt) | produto de combinação, uso de um produto de combinação, e, método para tratar câncer | |
| BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
| BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0814777A2 (pt) | Composto, composição farmacêutica, método para tratar um neoplasma, uso de um composto, e, composição farmacêutica. | |
| BRPI0908100A2 (pt) | produto combinação, uso de um composto, e, método de tratar câncer | |
| BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
| BRPI1015983A2 (pt) | composto, uso do composto, método para tratar um paciente, e, composição farmacêutica. | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| BRPI0914927A2 (pt) | composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto | |
| BRPI0815057A2 (pt) | Composto, composição farmacêutica, e, método para tratar infecção. | |
| BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
| BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
| BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
| BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| BR112012018947A8 (pt) | composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
| BRPI0816331A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. | |
| BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
| BRPI0906475A2 (pt) | Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto | |
| BRPI0908635A2 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| BRPI0818323A2 (pt) | composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |